Researchers at the University of California, San Francisco, have launched a new online database to help reduce the time and cost of conducting clinical trials for brain ailments.
The team concluded that a protein called REST--particularly active in the brains of fetuses and now emerging as a key gene regulator in older brains--also appears to protect neurons in the elderly.
Researchers at Shanghai Jiao Tong University in China have developed nanoparticles capable of crossing the blood-brain barrier that could potentially help to clear amyloid-β proteins, which are associated with Alzheimer's disease.
Certain biomarkers that can point to the presence of Alzheimer's build and then peak in the body over a period of years and then drop after symptoms appear, researchers have determined.
The big biotech worked a deal with Eisai, offering to cover half of the research and development costs of a pair of mid-stage Alzheimer's therapies and adding an unspecified package of milestones and an upfront in exchange for half the potential profits.
The healthcare burdens of aging populations have traditionally been a Western problem, but rising life expectancy in emerging markets has caused the pressures to spread around the world. In India, the co-founder of IT services firm Infosys has responded by funding a brain and computing research center to improve the health of the 100 million citizens aged over 60.
Crossing the blood-brain barrier is notoriously difficult, but overcoming that obstacle can have vast implications for the treatment of Alzheimer's, Huntington's and brain cancer. Now researchers at Roche have developed an antibody-based technique to "shuttle" large molecules into the brain, increasing exposure to the drug.
The Switzerland-based biotech has raised $22 million from German billionaire Dietmar Hopp and other backers to advance its Alzheimer's vaccine candidate, ACI-35, into clinical trials.
The game attempts to assess whether someone has Alzheimer's by evaluating how well they respond to distractions and interruptions.
When it comes to Alzheimer's research, success stories are few and far between. Therapeutic programs center around vaccines and drugs, but Akili Interactive Labs wants to change all that: The Boston-based startup recently signed a deal with Pfizer to see if its mobile video game platform can help diagnose early signs of Alzheimer's.